Everett Harris & Co. CA Has $6.02 Million Position in Amgen Inc. (NASDAQ:AMGN)

Everett Harris & Co. CA lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,102 shares of the medical research company’s stock after selling 586 shares during the period. Everett Harris & Co. CA’s holdings in Amgen were worth $6,021,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Capital Performance Advisors LLP bought a new stake in shares of Amgen in the 3rd quarter worth about $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the third quarter worth $29,000. Matrix Trust Co bought a new stake in shares of Amgen during the third quarter worth $36,000. Heck Capital Advisors LLC acquired a new position in Amgen during the 4th quarter worth about $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in Amgen in the 3rd quarter valued at about $56,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Amgen stock opened at $285.42 on Friday. The business has a 50 day moving average of $271.24 and a 200-day moving average of $304.84. The company has a market capitalization of $153.42 billion, a P/E ratio of 36.55, a P/E/G ratio of 2.85 and a beta of 0.56. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. On average, equities research analysts predict that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is currently 115.24%.

Analyst Ratings Changes

AMGN has been the topic of a number of recent research reports. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. UBS Group decreased their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Wolfe Research started coverage on shares of Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Finally, Citigroup dropped their target price on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.